~~~ UPDATE: FDA rejects Protalix's Uplyso (taliglucerase alfa) ~~~
Protalix (PLX) announced today that the company has received a CRL (complete response letter) from the US drug regulator, which requested additional data from the switch-over trial and extended follow-up study. PLX shares dove down 25% in morning trading. However, those who purchased Mar $12.5 put options are enjoying their 50% profit on Ulypso's refusal.
No comments:
Post a Comment